Dr. Ereshefsky is an internationally recognized key opinion leader in clinical translational central nervous system research with a proven track record in designing and performing first-in-human, proof-of-concept, and a broad range of Phase I clinical pharmacology studies. With over 30 years’ experience leading early phase research sites, he is utilized as a global resource within CenExel, providing support to ensure consistency and quality across sites. Dr. Ereshefsky is actively involved in strategic planning for compound development. He helps design translational research programs and define the critical path towards regulatory approval. He has extensive experience working with regulatory agencies and developing strategic plans to address compound differentiation and reimbursement challenges.

Dr. Ereshefsky has contributed significantly to many drug approvals, including by providing drug development planning, PK evaluation, and methodological innovation. He has introduced strategies to de-risk early phase drug development through the application of neurocircuitry/biomarker-based (RDoC) strategies, e.g., continuous CSF sampling, QEEG, ERPs, PSG, fMRI, PET, and cognitive and behavioral paradigms.

Dr. Ereshefsky is a retired Regents Professor of Pharmacy, Psychiatry, and Pharmacology from The University of Texas at Austin and University of Texas Health Science Center at San Antonio. Subsequently, he was EVP and CSO for California Clinical Trials from 2003 to 2008 when it was acquired by Parexel International where his role was VP, Principal Pharmacologist, and Therapeutic Area Leader for CNS Early Phase until his departure in 2016. Dr. Ereshefsky has published almost 150 peer-reviewed scholarly articles and abstracts. He received his Pharm.D. from the University of Southern California. His post Post-Graduate Residency in Psychiatric Pharmacy/Psychopharmacology was completed at Los Angeles County+USC Medical Center (LAC+USC).